Imperial College London
Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics. He was awarded a Breast Cancer Campaign Scientific Fellowship (Imperial, 2009-2014) and is now a Senior Lecturer (2014-present) in the Division of Cancer, Dept. of Surgery and Cancer, Faculty of Medicine at Imperial College London. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011 and is the principal investigator for the OCA funded programme "Risk and Prevention" based in the Ovarian Cancer Action Research Centre. Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis and investigating the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.
Epigenetic biomarkers for platinum response in ovarian cancer
Platinum based chemotherapy is the standard of care for ovarian cancer patients at first line treatment and often at subsequent relapses. We have identified and validated an epigenetic biomarker detectable in blood DNA that predicts whether a patient should be treated with platinum after relapse. We propose a mechanism by which platinum-adduct DNA repair causes the epigenetic changes and that the genomic and epigenomic location of platinum adducts defines sensitivity.
EVEN MORE SEMINARS
Simon Walker-Samuel University College London
Using medical imaging with machine learning to develop efficient tools for diagnosing cancer
Jocelyn Harding CEB DipDH Oralieve UK
The importance of mouth care for cancer patients
Christopher Curtis The Swallows Head & Neck Cancer Charity
From Cancer to the Palace in 6 years
Corina van den Hurk Netherlands Comprehensive Cancer Organisation
Hair loss through chemotherapy is not inevitable!
Khurum Khan Royal Marsden NHS Foundation Trust
Biomarkers of response and/or resistance to targeted therapies in refractory mCRC